Table 1

Baseline characteristics of patients with mitral stenosis

Total
(n=42 075)
MS with AF
(n=27 824)
MS without AF
(n=14 251)
P value
Age (years) (mean±SD)60.7±13.561.4±12.359.3±15.4<0.0001
Female gender, n (%)28 772 (68.4)18 734 (67.3)10 038 (70.4)<0.0001
Hypertension, n (%)38 335 (91.1)26 424 (95.0)11 911 (83.6)<0.0001
Diabetes mellitus, n (%)26 040 (61.9)18 201 (65.4)7839 (55.0)<0.0001
Previous stroke, n (%)12 252 (29.1)9586 (34.5)2666 (18.7)<0.0001
Congestive heart failure27 666 (65.8)21 047 (75.6)6619 (46.5)<0.0001
Previous vascular disease*19 724 (46.9)13 098 (47.1)6626 (46.5)0.26
CHA2DS2-VASc (mean±SD)4.2±1.84.4±1.73.8±1.9<0.0001
COPD9714 (23.1)6986 (25.1)2728 (19.1)<0.0001
CKD4126 (9.8)3025 (10.9)1101 (7.7)<0.0001
Drugs
 Aspirin27 745 (65.9)18 638 (67.0)9107 (63.9)<0.0001
 Clopidogrel12 942 (30.8)9002 (32.4)3940 (27.7)<0.0001
 Cilostazol4570 (10.9)3041 (10.9)1529 (10.7)0.53
 Ticlopidine932 (2.2)607 (2.2)325 (2.3)0.51
 Vitamin K antagonist30 344 (72.1)24 975 (89.8)5369 (37.7)<0.0001
  • *Previous vascular diseases defined as prior myocardial infarction, peripheral artery disease or aortic plaque.

  • AF, atrial fibrillation; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; MS, mitral stenosis.